Enterprise Value
3.425B
Cash
635.4M
Avg Qtr Burn
-53.56M
Short % of Float
15.64%
Insider Ownership
55.96%
Institutional Own.
48.60%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Batoclimab (IMVT-1401) Details Thyroid Eye Disease | Phase 3 Data readout | |
Phase 3 Data readout | ||
Batoclimab (IMVT-1401) Details Chronic inflammatory disorder | Phase 2b Data readout | |
Batoclimab (IMVT-1401) Details Graves’ disease | Phase 2 Data readout | |
IMVT-1402 Details Autoimmune disease, Warm autoimmune hemolytic anemia | Phase 1 Update | |
Batoclimab (IMVT-1401) Details Warm autoimmune hemolytic anemia | Failed Discontinued |